切换至 "中华医学电子期刊资源库"
高级检索
中华肝脏外科手术学电子杂志

中华肝脏外科手术学电子杂志 ›› 2021, Vol. 10 ›› Issue (01) : 98 -103. doi: 10.3877/cma.j.issn.2095-3232.2021.01.021

所属专题： 文献；

基础研究

基于生物信息学检测TRIM47基因在肝癌中的表达及意义
伍隽华1,†(), 顾娇娇2, 陈云扬1, 余杰雄1, 邝乃乐1, 黄皓川1   
  1. 1. 529000　广东省江门市中心医院肝胆外科
    2. 510630　广州，中山大学附属第三医院肝胆外科
  • 收稿日期:2020-10-20 出版日期:2021-02-10
  • 通信作者: 伍隽华
  • 基金资助:
    2019年度江门市中心医院科研启动基金资助项目(D201902)

Expression of TRIM47 and its significance in liver cancer base on bioinformatic test

Juanhua Wu1,†(), Jiaojiao Gu2, Yunyang Chen1, Jiexiong Yu1, Naile Kuang1, Haochuan Huang1   

  1. 1. Department of Hepatobiliary Surgery, Jiangmen Central Hospital, Jiangmen 529000, China
    2. Department of Hepatobiliary Surgery, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
  • Received:2020-10-20 Published:2021-02-10
  • Corresponding author: Juanhua Wu
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

伍隽华, 顾娇娇, 陈云扬, 余杰雄, 邝乃乐, 黄皓川. 基于生物信息学检测TRIM47基因在肝癌中的表达及意义[J]. 中华肝脏外科手术学电子杂志, 2021, 10(01): 98-103.

Juanhua Wu, Jiaojiao Gu, Yunyang Chen, Jiexiong Yu, Naile Kuang, Haochuan Huang. Expression of TRIM47 and its significance in liver cancer base on bioinformatic test[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2021, 10(01): 98-103.

目的

探讨三结构域蛋白47（TRIM47）基因在肝癌中的表达及其临床意义。

方法

通过生物信息学方法，利用UALCAN、HPA数据库分析TRIM47在肝癌中的基因表达和蛋白表达。利用Kaplan-Meier生存数据库分析肝癌患者总生存率，评估TRIM47在肝癌患者预后中的价值。利用cBioPortal数据库分析肝癌患者中TRIM47的基因突变频率，以及TRIM47基因突变对肝癌患者总生存率的影响。构建稳定表达TRIM47的肝癌细胞株Hep3B、Huh-7，采用qRT-PCR检测肝癌细胞TRIM47 mRNA，CCK-8法检测其细胞增殖能力。肝癌TRIM47 mRNA相对表达量和增殖能力比较采用秩和检验或t检验。

结果

UALCAN数据库分析显示肝癌组织中TRIM47 mRNA相对表达量中位数为18.95（10.79，31.81），明显高于正常肝组织中的7.09（5.76，9.61） （P<0.05）。HPA数据库分析显示肝癌组织中TRIM47蛋白水平呈高表达，而在正常肝组织中呈低表达。UALCAN数据库分析显示随着肿瘤组织中TRIM47表达水平的升高，患者临床分期、肿瘤分级越差（P<0.05）。Kaplan-Meier生存数据库分析显示低表达TRIM47的肝癌患者总体生存期更长（HR=1.59，95%CI：1.12～2.26；P<0.05）。cBioPortal数据库分析显示TRIM47在肝癌患者中的基因突变率可达14%，且能明显影响患者总生存率（P=0.013 6）。Hep3B-TRIM47和Huh-7-TRIM47肝癌细胞TRIM47 mRNA平均相对表达量分别为（4.87±0.14）×10-3、（2.47±0.47）×10-3，明显高于对照组的（0.60±0.08）×10-3、（0.18±0.05）×10-3（t=26.560，4.856；P<0.05）。Hep3B-TRIM47和Huh-7-TRIM47肝癌细胞株增殖能力显著增强。

结论

TRIM47基因可通过促进肝癌细胞增殖影响肝癌患者的预后，TRIM47可能成为预测肝癌患者预后的一种新型标记物。

关键词: 癌, 肝细胞, 细胞增殖, TRIM47基因, 计算生物学
Objective

To investigate the expression and clinical significance of tripartite motif-containing 47 (TRIM-47) gene in liver cancer.

Methods

The expression of TRIM47 mRNA and protein in liver cancer were analyzed by bioinformatics methods using UALCAN and HPA databases. The overall survival of liver cancer patients was analyzed by Kaplan-Meier survival database. The prognostic value of TRIM47 in liver cancer patients was evaluated. The frequency of TRIM47 gene mutation was analyzed by cBioPortal database. The effect of TRIM47 gene mutation on the overall survival of liver cancer patients was assessed. The liver cancer cell lines Hep3B and Huh-7 which stably expressed TRIM47 were constructed. The expression of TRIM47 mRNA in liver cancer cells was detected by qRT-PCR. The cell proliferation ability was detected by CCK-8 assay. The relative expression of TRIM47 mRNA and the proliferation ability of liver cancer cells were compared by rank-sum test or t test.

Results

UALCAN database analysis showed that the median relative expression of TRIM47 mRNA in liver cancer tissues was 18.95(10.79, 31.81), significantly higher than 7.09(5.76, 9.61) in normal liver tissues (P<0.05). HPA database analysis demonstrated that TRIM47 protein highly expressed in liver cancer tissues, whereas lowly expressed in normal liver tissues. UALCAN database revealed that with the up-regulation of TRIM47 expression in tumor tissues, the clinical stage and tumor grade became significantly worse (both P<0.05). Kaplan-Meier survival database analysis showed that the overall survival of liver cancer patients with low expression of TRIM47 was significantly longer (HR=1.59, 95%CI: 1.12-2.26; P<0.05). cBioPortal database analysis indicated that the mutation rate of TRIM47 gene in patients with liver cancer reached up to 14%, and significantly affected the overall survival (P=0.013 6). The mean relative expression levels of TRIM47 mRNA in Hep3B-TRIM47 and Huh-7-TRIM47 liver cancer cells were (4.87±0.14)×10-3 and (2.47±0.47)×10-3, significantly higher than (0.60±0.08)×10-3 and (0.18±0.05)×10-3 in the control group (t=26.560, 4.856; P<0.05). The proliferation ability of Hep3B-TRIM47 and Huh-7-TRIM47 cell lines was significantly enhanced.

Conclusions

TRIM47 can affect the clinical prognosis of patients with liver cancer by promoting the proliferation of liver cancer cells. TRIM47 may become a novel biomarker for predicting the prognosis of liver cancer patients.

Key words: Carcinoma, hepatocellular, Cell proliferation, TRIM47 gene, Computational biology
图1 不同数据库肝癌组织中TRIM47的表达谱
图2 UALCAN数据库分析TRIM47表达水平与肝癌患者临床特征之间的关系
图3 TRIM47在肝癌中的突变情况及对患者生存的影响
图4 TRIM47过表达组与对照组细胞生长曲线
[1]
Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(10):589-604.
[2]
Li C, Li R, Zhang W. Progress in non-invasive detection of liver fibrosis[J]. Cancer Biol Med, 2018, 15(2):124-136.
[3]
Forner A, Reig M, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127):1301-1314.
[4]
Dawkins J, Webster RM. The hepatocellular carcinoma market[J]. Nat Rev Drug Discov, 2019, 18(1):13-14.
[5]
Hatakeyama S. TRIM family proteins: roles in autophagy, immunity, and carcinogenesis[J]. Trends Biochem Sci, 2017, 42(4):297-311.
[6]
Hatakeyama S. TRIM proteins and cancer[J]. Nat Rev Cancer, 2011, 11(11):792-804.
[7]
Fujimura T, Inoue S, Urano T, et al. Increased expression of tripartite motif (TRIM) 47 is a negative prognostic predictor in human prostate cancer[J]. Clin Genitourin Cancer, 2016, 14(4):298-303.
[8]
Li W, Zhang W, Deng W, et al. Quantitative proteomic analysis of mitochondrial proteins differentially expressed between small cell lung cancer cells and normal human bronchial epithelial cells[J]. Thorac Cancer, 2018, 9(11):1366-1375.
[9]
Liang Q, Tang C, Tang M, et al. TRIM47 is up-regulated in colorectal cancer, promoting ubiquitination and degradation of SMAD4[J].J Exp Clin Cancer Res, 2019, 38(1):159.
[10]
Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses[J]. Neoplasia, 2017, 19(8):649-658.
[11]
Asplund A, Edqvist PH, Schwenk JM, et al. Antibodies for profiling the human proteome-the human protein Atlas as a resource for cancer research[J]. Proteomics, 2012, 12(13):2067-2077.
[12]
Hou GX, Liu P, Yang J, et al. Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan-Meier plotter[J]. PLoS One, 2017, 12(3):e0174515.
[13]
Popovic D, Vucic D, Dikic I. Ubiquitination in disease pathogenesis and treatment[J]. Nat Med, 2014, 20(11):1242-1253.
[14]
Micale L, Chaignat E, Fusco C, et al. The tripartite motif: structure and function[J]. Adv Exp Med Biol, 2012(770):11-25.
[15]
Cambiaghi V, Giuliani V, Lombardi S, et al. TRIM proteins in cancer[J]. Adv Exp Med Biol, 2012(770):77-91.
[16]
Zhou Z, Liu Y, Ma M, et al. Knockdown of TRIM44 inhibits the proliferation and invasion in papillary thyroid cancer cells through suppressing the Wnt/β-catenin signaling pathway[J]. Biomed Pharmacother, 2017(96):98-103.
[17]
Huang XQ, Zhang XF, Xia JH, et al. Tripartite motif-containing3 (TRIM3) inhibits tumor growth and metastasis of liver cancer[J]. Chin J Cancer, 2017, 36(1):77.
[18]
Li L, Dong L, Qu X, et al. Tripartite motif 16 inhibits hepatocellular carcinoma cell migration and invasion[J]. Int J Oncol, 2016, 48(4): 1639-1649.
[19]
Han Y, Tian H, Chen P, et al. TRIM47 overexpression is a poor prognostic factor and contributes to carcinogenesis in non-small cell lung carcinoma[J]. Oncotarget, 2017, 8(14):22730-22740.
[1] 李淼, 朱连华, 韩鹏, 姜波, 费翔. 高帧频超声造影评价肝细胞癌血管形态与风险因素的研究[J]. 中华医学超声杂志（电子版）, 2023, 20(09): 911-915.
[2] 钱龙, 陆晓峰, 王行舟, 杜峻峰, 沈晓菲, 管文贤. 神经系统调控胃肠道肿瘤免疫应答研究进展[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 86-89.
[3] 叶晓琳, 刘云飞, 庞明泉, 王海久, 任利, 侯立朝, 于文昊, 王志鑫, 樊海宁. 肝再生细胞来源及调控机制的研究进展[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 96-99.
[4] 尚培中, 张润萍, 张伟, 贾国洪, 李晓武, 苗建军, 刘冰. 梗阻性黄疸临床防治新技术单中心应用研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 104-107.
[5] 彭旭, 邵永孚, 李铎, 邹瑞, 邢贞明. 结肠肝曲癌的诊断和外科治疗[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 108-110.
[6] 马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[7] 曹迪, 张玉茹. 经腹腔镜生物补片修补直肠癌根治术后盆底疝1例[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 115-116.
[8] 姚宏伟, 魏鹏宇, 高加勒, 张忠涛. 不断提高腹腔镜右半结肠癌D3根治术的规范化[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 1-4.
[9] 杜晓辉, 崔建新. 腹腔镜右半结肠癌D3根治术淋巴结清扫范围与策略[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 5-8.
[10] 张生军, 赵阿静, 李守博, 郝祥宏, 刘敏丽. 高糖通过HGF/c-met通路促进结直肠癌侵袭和迁移的实验研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 21-24.
[11] 杨倩, 李翠芳, 张婉秋. 原发性肝癌自发性破裂出血急诊TACE术后的近远期预后及影响因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 33-36.
[12] 冯冰, 邹秋果, 梁振波, 卢艳明, 曾奕, 吴淑苗. 老年非特殊型浸润性乳腺癌超声征象与分子生物学指标的临床研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 48-51.
[13] 栗艳松, 冯会敏, 刘明超, 刘泽鹏, 姜秋霞. STIP1在三阴性乳腺癌组织中的表达及临床意义研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 52-56.
[14] 李永胜, 孙家和, 郭书伟, 卢义康, 刘洪洲. 高龄结直肠癌患者根治术后短期并发症及其影响因素[J]. 中华临床医师杂志(电子版), 2023, 17(9): 962-967.
[15] 袁媛, 赵良平, 刘智慧, 张丽萍, 谭丽梅, 閤梦琴. 子宫内膜癌组织中miR-25-3p、PTEN的表达及与病理参数的关系[J]. 中华临床医师杂志(电子版), 2023, 17(9): 1016-1020.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号